$IMNM insider trading
Over the last 12 months, Immunome insiders reported 7 buys totaling $2.2M and 16 sales totaling $27.5M across SEC Form 4 filings. 61% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $2.2M 7 events
- Sold · 12m
- $27.5M 16 events
- Events · 12m
- 23 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 61% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins JackChief Scientific Officer · O | ▼ Sale | 13,200 | $25.32 | $334K | -16.9% | plan |
| Aug 12, 2026 | Barchas IsaacD | ▼ Sale | 11,048 | $27.25 | $301K | -10.7% | plan |
| Aug 11, 2026 | Barchas IsaacD | ▼ Sale | 72,416 | $26.21 | $1.9M | -100% | plan · 2 tranches · indirect |
| Aug 7, 2026 | Barchas IsaacD | ▼ Sale | 36,088 | $26.06 | $940K | -33.3% | plan · 2 tranches · indirect |
| Aug 4, 2026 | Horn KinneyCHIEF BUSINESS OFFICER · O | ▼ Sale | 90,616 | $25.09 | $2.3M | -100% | plan |
| Jul 7, 2026 | Horn KinneyCHIEF BUSINESS OFFICER · O | ▼ Sale | 1,092 | $25 | $27K | -100% | plan |
| Jul 7, 2026 | Barchas IsaacD | ▼ Sale | 100,000 | $24.13 | $2.4M | -48% | plan · 2 tranches · indirect |
| Jul 2, 2026 | Barchas IsaacD | ▼ Sale | 201,050 | $21.85 | $4.4M | -49.1% | plan · 3 tranches · indirect |
| Jul 2, 2026 | Lechleider RobertChief Medical Officer · O | ▼ Sale | 55,000 | $22.62 | $1.2M | -77.7% | plan · 3 tranches |
| Jun 25, 2026 | Lechleider RobertChief Medical Officer · O | ▼ Sale | 55,000 | $19.85 | $1.1M | -77.7% | plan · 2 tranches |
| Jun 15, 2026 | Rosett MaxChief Financial Officer · O | ▼ Sale | 60,000 | $18.23 | $1.1M | -52.6% | plan |
| Jun 5, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 10,500 | $19.45 | $204K | +31.9% | 3 tranches |
| Jun 5, 2026 | BIENAIME JEAN JACQUESD | ▼ Sale | 10,500 | $19.41 | $204K | -24.2% | 2 tranches |
| Apr 2, 2026 | Rosett MaxChief Financial Officer · O | ▼ Sale | 65,000 | $21.92 | $1.4M | -54.6% | plan · 2 tranches |
| Apr 2, 2026 | Higgins JackChief Scientific Officer · O | ▼ Sale | 9,438 | $21.64 | $204K | -30% | plan |
| Mar 27, 2026 | SIEGALL CLAY BPresident and CEO · O·D | ▲ Buy | 25,450 | $19.67 | $501K | +3.8% | — |
| Mar 23, 2026 | WAGENHEIM PHILIPD | ▼ Sale | 65,000 | $20.55 | $1.3M | -16% | 2 tranches |
| Mar 11, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 2,000 | $21.84 | $44K | +5.5% | 2 tranches |
| Dec 30, 2025 | SIEGALL CLAY BPresident and CEO · O·D | ▲ Buy | 4,729 | $21.15 | $100K | +0.7% | — |
| Dec 22, 2025 | Barchas IsaacD | ▼ Sale | 383,200 | $21.74 | $8.3M | -15.9% | plan · 2 tranches · indirect |
| Dec 19, 2025 | Tsai PhilipChief Technical Officer · O | ▲ Buy | 10,000 | $20.49 | $205K | +30% | — |
| Dec 19, 2025 | SIEGALL CLAY BPresident and CEO · O·D | ▲ Buy | 7,278 | $20.48 | $149K | +0.9% | — |
| Dec 18, 2025 | SIEGALL CLAY BPresident and CEO · O·D | ▲ Buy | 46,511 | $21.5 | $1000K | +5.8% | — |
Every $IMNM filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Immunome filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IMNM feed.